Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00000389
DRKS00000389
Completed
Phase 4

Three-armed study for therapy of primary and secondary syphilis in HIV infection

St. Josef HospitalInterdisziplinäre Immunologische Ambulanz0 sites115 target enrollmentMay 25, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsA53.9Syphilis, unspecified

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
A53.9
Sponsor
St. Josef HospitalInterdisziplinäre Immunologische Ambulanz
Enrollment
115
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 25, 2010
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
St. Josef HospitalInterdisziplinäre Immunologische Ambulanz

Eligibility Criteria

Inclusion Criteria

  • •HIV positive Patients with serologically proven early syphilis

Exclusion Criteria

  • •\-known sensibilization agaist ß\-lactam antibiotics
  • •\-patients that were treated within the last 48h with an agent that is active against treponema pallidum
  • •\-pregnant or lactating women
  • •\-patients with late syphilis (latent syphilis of unknown duration, tertiary syphilis or neuro syphilis

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
A phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil (DCF) vs definitive chemoradiotherapy for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus(JCOG1510,TRIANgLE)locally advanced unresectable squamous cell carcinoma of the thoracic esophagus
JPRN-UMIN000031165Japan Clinical Oncology Group (JCOG)230
Completed
Phase 2
Phase II Study of a Quadruple-modality Therapy for Resectable Stage Discrete N2 III A-B Non-small Cell Lung Cancer (WJOG12119L: SQUAT trial)
JPRN-jRCT2080224981Tetsuya Mitsudomi (Coordinating Investigator)31
Active, not recruiting
Phase 1
A Clinical Study in Three-arm of Lurbinectedin (PM01183) alone or in combination with Gemcitabine and a control arm with Docetaxel as second-line treatment in Small Cell Lung Cancer (NSCLC) patients.nresectable Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-000548-25-BEPharma Mar S.A. Sociedad Unipersonal120
Active, not recruiting
Not Applicable
A Clinical Study in Three-arm of Lurbinectedin (PM01183) alone or in combination with Gemcitabine and a control arm with Docetaxel as second-line treatment in Small Cell Lung Cancer (NSCLC) patients.nresectable Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-000548-25-FRPharma Mar S.A. Sociedad Unipersonal120
Active, not recruiting
Phase 1
A Clinical Study in Three-arm of Lurbinectedin (PM01183) alone or in combination with Gemcitabine and a control arm with Docetaxel as second-line treatment in Small Cell Lung Cancer (NSCLC) patients.nresectable Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 16.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-000548-25-ITPharma Mar S.A. Sociedad Unipersonal120